Drugs / Nimacimab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03261739 | Aug 2017 → Aug 2018 | fatty liver disease | Bird Rock Bio, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06577090 | Aug 2024 → Nov 2026 expected | obesity disorder | Skye Bioscience, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03900325 | Aug 2019 → Jan 2020 | gastroparesis | Bird Rock Bio, Inc. | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nimacimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03900325 ↗ |
| Known as | JNJ-2463 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298095 ↗ |
| Known as | RYI-018 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03261739 ↗ |
| Action | Inhibit | “Cannabinoid CB1 receptor negative allosteric modulator” CHEMBL4298095 ↗ |
| Modality | Monoclonal antibody | “Anti-CB1 monoclonal antibody” NCT03261739 ↗ |
| Route | Intravenous | “repeat IV doses of RYI-018” NCT03261739 ↗ |
| Target | CNR1 | “Cannabinoid CB1 receptor negative allosteric modulator” CHEMBL4298095 ↗ |